PharmaShots’ Post

Bristol Myers Squibb Presents the Long-Term P-III (MAVA-LTE) Trial Data of Camzyos to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) #bms #camzyos #symptomaticobstructivehypertrophiccardiomyopathy #clinicaltrial #phase3 #mavalte

Pharmacogenomics is revolutionizing how we approach treatment. By understanding patients’ genetic profiles, pharmacists can now tailor medication choices, leading to more effective therapies and fewer adverse reactions. Studies show that up to 30% of patients experience adverse drug reactions that could be avoided with pharmacogenomic testing. Pharmacogenomics has been shown to improve medication efficacy by 25-30%, optimizing treatment plans for better patient outcomes. As pharmacists, embracing this science enables us to go beyond the one-size-fits-all approach and offer truly personalized care. How are you incorporating pharmacogenomics into your practice? #Pharmacogenomics #PersonalizedMedicine #PharmacyInnovation #PrecisionMedicine #BetterOutcomes

Multiple Sclerosis Market Assessment 2034 | Multiple Sclerosis Therapies, FDA Approval, Clinical trials, Prevalence, Treatment Algorithms and Companies by DelveInsight | Immune Response BioPharma: Multiple Sclerosis Market As per DelveInsight, the Multiple Sclerosis Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Multiple Sclerosis in the 7MM. DelveInsight’s … Continue reading → #Business #Europe #HealthMedicine #PharmaceuticalsBiotech #US

#DYK about 16 million Americans experience gastroparesis symptoms, and the majority go untreated as there is no chronic treatment option?     CinDome Pharma is enrolling the #envision3d clinical trial to investigate deudomperidone (CIN-102) as a potential, chronic therapy for gastroparesis and fill this unmet medical need. Learn more about our work at: cindome.com and www.gastroparesistrial.com #GastroparesisAwarenessMonth #GastroparesisAwareness #LivingWithGP 

A recent consensus from an international task force highlights the urgent need for clinical trials focusing on alcohol use and its impact on liver disease. The expert recommendations, published by UT Southwestern Medical Center in Nature, stress the importance of addressing the stigma associated with alcohol use disorder (AUD) and alcohol-related liver disease (ALD). These insights align with Adial Pharmaceuticals (NASDAQ: ADIL) and their commitment to developing innovative treatments for AUD, reinforcing the need for collaborative and stigma-free research efforts. For more: https://bit.ly/3zB0Pd4 #AUD #ClinicalTrials #HealthcareInnovation #HealthResearch

🧠 SetPoint Medical reports positive results from neuroimmune modulation device study SetPoint System is a neuroimmune modulation device that showed a clinical benefit in adults living with moderate-to-severe rheumatoid arthritis (RA). RESET-RA is a two-staged, multicentre, randomised, sham-controlled, double-blind clinical trial that enrolled a total of 242 patients across 41 sites in the US. The study evaluated the system as a potential neuroimmune modulation treatment for RA patients who are intolerant to disease-modifying anti-rheumatic drugs (DMARDs). Read more online: https://lnkd.in/eErbvxEM 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

Modern treatments depend heavily on the development of sophisticated sustained-release dosage forms, which offer consistent drug delivery, lower dosage frequency, and enhance patient adherence to treatment plans. For chronic disorders like cardiovascular diseases, where stable plasma medication levels might avoid oscillations that result in negative events, these developments are especially revolutionary. These formulations, which incorporate cutting-edge technologies and creative excipients, not only improve therapeutic results but also tackle issues like reducing side effects and customizing drug release to suit patient requirements and lifestyles.

We are evaluating the effectiveness of our investigational oral therapy for #ThyroidEyeDisease (TED) in a Phase 2b/3 clinical trial. Learn more about LIDS: https://lnkd.in/e4xE8anj

Developing advanced sustained-release dosage forms ensures consistent therapeutic effects, enhanced patient compliance, and optimized drug delivery. These systems are especially impactful in managing chronic conditions like cardiovascular diseases, where controlled, precise drug release can improve outcomes and quality of life. SmaBio Labs leverages cutting-edge formulation techniques and innovative release mechanisms to design solutions tailored to your molecule's unique properties. From concept to commercialization, we ensure efficiency and precision at every stage of development. Curious about the science behind sustained-release formulations and their role in cardiovascular therapies? Visit smabiolabs.com to explore the details. #SustainedRelease #DrugDelivery #CDMO #Innovation #SmaBioLabs #cardiovascularmedication

#ACTRIMS2024: #BMS presented long-term data of #Zeposia in patients with Relapsing Forms of #MultipleSclerosis https://lnkd.in/gxbGkBVj #BREAKING #news #pharma #pharmaceutical #Science #TeleMedicine #media #medicine #healthcare #MedComms #Medical #PatientSafety #ACTRIMS